CABR · Caring Brands, Inc. · Insider Trading

On October 6, 2026, at the recommendation of the Issuer's Compensation Committee, the Issuer's Board of Directors approved this option grant under the Company's equity incentive plan.

The options vested immediately on October 6, 2026.

The number of shares of common stock beneficially owned following the reported transaction also includes the Reporting Person's ownership of (i) 126,720 restricted stock units of common stock of the Issuer of which zero have vested, (ii) 45,872 restricted stock units of common stock of the Issuer of which zero have vested, and (iii) 500,000 shares of common stock.

On September 28, 2026, at the recommendation of the Issuer's Compensation Committee, the Issuer's Board of Directors approved this option grant under the Company's equity incentive plan.

The options vested immediately on September 28, 2026.

On September 28, 2026, at the recommendation of the Issuer's Compensation Committee, the Issuer's Board of Directors approved this option grant under the Company's equity incentive plan.

The options vested immediately on September 28, 2026.

Includes the options previously issued to the Reporting Person.

On September 28, 2026, at the recommendation of the Issuer's Compensation Committee, the Issuer's Board of Directors approved this option grant under the Company's equity incentive plan.

The options vested immediately on September 28, 2026.

Includes the options previously issued to the Reporting Person.

On September 28, 2026, at the recommendation of the Issuer's Compensation Committee, the Issuer's Board of Directors approved this option grant under the Company's equity incentive plan.

The options vested immediately on September 28, 2026.

Includes the options previously issued to the Reporting Person.

Represents redemption of 150,000 shares of common stock of the Issuer at approximately $1.00 per share pursuant to that certain Share Redemption Agreement dated July, 10, 2026, by and between the Issuer and BK Investments LLC, an entity owned by the Reporting Person, the Issuer's Chairman and Interim Chief Financial Officer.

Represents redemption of 1,250,000 shares of common stock of the Issuer at approximately $1.00 per share pursuant to that certain Share Redemption Agreement signed by the Reporting Person and the Issuer on March 19, 2026.

Represents redemption of 1,500,000 shares of common stock of the Issuer at approximately $0.50 per share pursuant to that certain Share Redemption Agreement signed by the Reporting Person and the Issuer on March 19, 2026.

The number of shares of common stock beneficially owned following the reported transaction includes Dr. Wilson's ownership of (i) 126,720 restricted stock units of common stock of the Issuer of which zero have vested, (ii) 45,872 restricted stock units of common stock of the Issuer of which zero have vested, and (iii) 500,000 shares of common stock.

On December 11, 2025, on recommendation of the Compensation Committee of the Board of the Issuer, the Board approved the issuance of 45,872 restricted stock units of common stock of the Issuer, under its equity incentive plan. The RSU shares will fully vest on December 11, 2026. The vesting of shares is subject to Dr. Wilson's continued service with the Company.

The number of shares of common stock beneficially owned following the reported transactions includes Dr. Wilson's ownership of 2,000,000 shares of common stock.

On December 11, 2025, on recommendation of the Compensation Committee of the Board of Directors ("Board") of the Issuer, the Board approved the issuance of 270,000 restricted stock units of common stock of the Issuer, under its equity incentive plan. The RSU shares will fully vest on June 11, 2026. The vesting of shares is subject to Mr. Moore's continued services with the Company.

On December 11, 2025, at the recommendation of the Issuer's Compensation Committee, the Issuer's Board of Directors approved this option grant under the Company's equity incentive plan.

The options vested immediately on December 11, 2025.

On December 11, 2025, at the recommendation of the Issuer's Compensation Committee, the Issuer's Board of Directors approved this option grant under the Company's equity incentive plan.

The options vested immediately on December 11, 2025.

On December 11, 2025, at the recommendation of the Issuer's Compensation Committee, the Issuer's Board of Directors approved this option grant under the Company's equity incentive plan.

The options vested immediately on December 11, 2025.

On December 11, 2025, on recommendation of the Compensation Committee of the Board of the Issuer, the Board approved the issuance of 30,000 restricted stock units of common stock of the Issuer, under its equity incentive plan. The RSU shares will fully vest on December 11, 2026. The vesting of shares is subject to Mr. Moore's continued service with the Company.

On December 11, 2025, at the recommendation of the Issuer's Compensation Committee, the Issuer's Board of Directors approved the grant of 100,000 options, under the Company's equity incentive plan.

The options shall fully vest on June 11, 2026. Vesting of options is subject to the Reporting Person's continued services with the Issuer.

Does not include the 2,000,000 shares of common Stock of the Issuer owned by the Reporting Person.

On December 11, 2025, on recommendation of the Compensation Committee of the Board of Directors ("Board") of the Issuer, the Board approved the issuance of 126,720 restricted stock units of common stock of the Issuer, under its equity incentive plan. The RSU shares will fully vest on June 11, 2026. The vesting of shares is subject to Dr. Wilson's continued services with the Company.

The number of shares of common stock beneficially owned following the reported transactions includes Dr. Wilson's ownership of 2,000,000 shares of common stock.